#Medicina de Familia |📢 Los profesionales de la #atención primaria pueden y deben detectar la #hipercolesterolemia familiar (HF). 📄 Un estudio en la Comunidad de Madrid en @ATHjournal arroja datos sólidos y concluyentes. ✍ @alilo1920.

Aortic Plaques are More Thrombogenic Than Carotid and Femoral Plaques @ATHjournal | @society_eas https://t.co/9bCoVJU84U #Atherosclerosis #AtheroscleroticPlaques #Collagen #Plaques #Health #Thrombosis #Hematology #MedEd #EuropeanAtherosclerosisSociety #Hemostasis #MedX

We had excellent lectures during @society_eas YF meeting: Prof. Jan Boren, Editor-in-Chief of @ATHjournal, talked about Apo-B lipoproteins and ASCVD. Prof. Shoaib Afzal presented all about Mandelian randomization. Prof. Laurent Yvan-Charvet presented immunometabolism issues.

#Medicina de Familia |📢 Los profesionales de la #atención primaria pueden y deben detectar la #hipercolesterolemia familiar (HF). 📄 Un estudio en la Comunidad de Madrid en @ATHjournal arroja datos sólidos y concluyentes. ✍ @alilo1920.

Remnant cholesterol and particle number of VLDL subfractions in coronary artery disease: Pros and consUnderstanding the Emerging Role of Remnant Cholesterol & VLDL Subfractions in Coronary Disease 👉Growing evidence from large epidemiological cohorts and Mendelian randomization

🚨 New publication alert 🙌Our last manuscript is published in @ATHjournal : “Lipid-Lowering Therapies in Chronic Kidney Disease: A Call to Action.” 👉Key highlights: 1⃣CKD is a major and independent risk factor for ASCVD. 2⃣CKD patients are still underrepresented in LLT

👉Not all fibrates are created equal — and it’s time we stop pretending they are. 1️⃣ Decades of data, one clear message: fenofibrate stands alone in lowering apoB, non-HDL-C, and triglycerides — the true drivers of residual cardiovascular risk. 2️⃣ Pemafibrate? Potent in the

👉Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and CVD 🫀MASLD: not just a liver disease 👉Nearly 40% of adults worldwide have metabolic dysfunction–associated steatotic liver disease. But what kills most of them isn’t liver failure —

📖 Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors and cardiovascular disease Beyond a hepatic injury ! https://t.co/LrfTkmSd4Q @society_eas @ATHjournal #MASLD

🙌🏼 State-of-the-art review: 👉Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know ☝️This comprehensive review dissects the biological complexity and clinical significance of triglyceride-rich lipoproteins

Our latest study, now published in @ATHjournal, investigates HMGB1 as a therapeutic target in AAA. In collaboration w/ @ionispharma & using an ASO, we silenced HMGB1 and observed: ✅ Reduced aneurysm formation ✅ Lower atherosclerotic burden Read more: https://t.co/l1i58oOKT3

👉Understanding MASLD — from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist MASLD not only drives liver injury but also worsens lipid metabolism, fueling atherogenic dyslipidemia: ↑ VLDL, small dense LDL, dysfunctional HDL. The

Check the full publication in @ATHjournal 🔗 https://t.co/YFAEpBq8pH

Thread 3 Cont' @jamus_marcelo @cherskams @niharika_reddy9 @HanCardiomd @javierrcarrio

Thread 2 Cont't @SABOURETCardio @MeralKayikcoglu @LaleTokgozoglu @FedericaFogacci @JamalRanaMD @maciejbanach

#ESCCongress2025 @escardio and @society_eas update on 2019 guidelines for dyslipidemia management. Note extreme risk peofile, intensification of LDL lowering Rx in ACS and add-on EZE, , use of Vascrpa in hypertrgl and statins in HIV regardless of LDLc levels @Drlipid @AmarPut

@jamus_marcelo @cherskams @niharika_reddy9 @HanCardiomd @javierrcarrio Thread 4 - You csn find the update on @ATHjournal 👇👇 https://t.co/s1A9sCFIne

Congratulations to @fhpatienteurope for leading the charge and having the FIRST international cost-effectiveness study on Lp(a) testing published in Atherosclerosis, a leading journal in cardiovascular and lipid research. Its findings provide valuable economic evidence to

🧬New study in @ATHjournal confirms: routine Lp(a) testing improves #cardiovascular risk stratification & saves costs. Routine testing reclassifies 20% as high-risk, prevents #CVD events & saves costs across #health systems. Read the study: https://t.co/i26ob16G9u

Lipoprotein(a) Doesn’t Budge: New Atherosclerosis study (Koller et al., 2025) shows Lp(a) levels stay remarkably stable over 3.2 yrs. -✅ 91.6% stayed in same risk category -⚠️ Variability mostly due to lab error, not biology Link➡️ https://t.co/SdchkF15Jd @society_eas